Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance

Journal of Virology

Volumn 78, Issue 13, 2004, Pages 7079-7088

  Lu, Xiaobin ^a   Yu, Qiao ^a   Binder, Gwendolyn K ^a   Chen, Ziping ^a   Slepushkina, Tatiana ^a   Rossi, John ^b   Dropulic, Boro ^a,c  

^a VIRxSYS Corporation   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LENTIVIRUS VECTOR; RETROVIRUS VECTOR;

ARTICLE; CONTROLLED STUDY; GENE CONSTRUCT; GENE DELETION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN MODIFICATION; VIRAL GENE DELIVERY SYSTEM; VIRUS ATTENUATION; VIRUS CULTURE; VIRUS ENVELOPE; VIRUS GENE; VIRUS INHIBITION; VIRUS MUTANT; VIRUS REPLICATION; VIRUS RESISTANCE; VRX494 VECTOR;

BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELLS, CULTURED; GENE PRODUCTS, ENV; GENETIC VECTORS; HIV-1; HUMANS; LENTIVIRUS; MOLECULAR SEQUENCE DATA; MUTATION; RNA, ANTISENSE; SEQUENCE DELETION; TRANSDUCTION, GENETIC; VIRUS REPLICATION;

EID: 2942639506     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.13.7079-7088.2004     Document Type: Article

References (50)

1. Adachi, A., H.-E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M.-A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Baum, C., J. Dullmann, L. Zhixiong, B. Fehse, J. Meyer, D. A. Williams, and C. von Kalle. 2003. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 101:2099-2113.
3. Behrens, G. M., M. Stoll, and R. E. Schmidt. 2000. Lipodystrophy syndrome in HIV infection. What is it, what causes it, and how can it be managed? Drug Safety 23:57-76.
4. Boden, D., O. Pusch, F. Lee, L. Tucker, and B. Ramratnam. 2003. Human immunodeficiency virus type 1 escape from RNA interference. J. Virol. 77:11531-11535.
5. Centers for Disease Control and Prevention. 2002. Cases of HIV infection and AIDS in the United States, 2002. HIV/AIDS surveillance report, vol. 14. CDC Division of HIV/AIDS Prevention, Atlanta, Ga.
6. Chadwick, D. R., and A. M. Lever. 2000. Antisense RNA sequences targeting the 5′ leader packaging signal region of human immunodeficiency virus type-1 inhibits viral replication at post-transcriptional stages of the life cycle. Gene Ther. 7:1362-1368.
7. Coburn, G. A., and B. R. Cullen. 2002. Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J. Virol. 76:9225-9231.
8. Das, A. T., T. R. Brummelkamp, E. M. Westerhout, M. Vink, M. Madiredjo, R. Bernards, and B. Berkhout. 2004. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J. Virol. 78:2601-2605.
9. Davis, B., L. Humeau, and B. Dropulic. 2003. In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication. Mol. Ther. 9:160-172.
10. Donahue, R. E., B. A. Bunnell, M. C. Zink, M. E. Metzger, R. P. Westro, M. R. Kirby, T. Unangst, J. E. Clements, and R. A. Morgan. 1998. Reduction in SIV replication in rhesus macaques infused with autologous lymphocytes engineered with antiviral genes. Nat. Med. 4:181-186,
11. Dropulic, B., D. A. Elkins, J. J. Rossi, and N. Sarver. 1993. Ribozymes: use as anti-HIV therapeutic molecules. Antisense Res. Dev. 3:87-94.
12. Dropulic, B., M. Hermankova, and P. M. Pitha. 1996. A conditionally replicating HIV-1 vector interferes with wild type HIV-1 replication and spread. Proc. Natl. Acad. Sci. USA 93:11103-11108.
13. Freed, E. O, and M. A. Martin. 2001. HIVs and their replication, pp. 1971-2041. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, Pa.
14. Gacon, G., S. Gisselbrecht, J. P. Piau, J. P. Boissel, J. Tolle, and S. Fischer. 1982. High level of tyrosine protein kinase in a murine lymphoma cell line induced by Moloney leukemia virus. EMBO J. 1:1579-1582.
15. Hacein-Bey-Abina, S., C. von Kalle, M. Schmidt, M. P. McCormack, N. Wulffraat, P. Leboulch, A. Lim, C. S. Osborne, R. Pawlick, E. Morillon, R. Sorenson, A. Forster, P. Frase, J. I. Cohen, G. de Saint Basile, I. Alexander, U. Wintergerst, T. Frebourg, A. Aurias, D. Stoppa-Lyonnet, S. Romana, I. Radfort-Weiss, F. Gross, F. Valensi, E. Delabesse, E. Macintyre, F. Sigaux, J. Soulier, L. E. Leiva, M. Wissler, C. Prinz, T. H. Rabbitts, F. Le Deist, A. Fischer, and M. Cavazzana-Calvo. 2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415-419.
16. Hacein-Bey Abina, S., C. von Kalle, M. Schmidt, F. Le Deist, N. Wulffraat, E. McIntyre, I. Radford, J. L. Villeval, C. C. Fraser, M. Cavazzana-Calvo, and A. A. Fischer. 2003. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348:255-256.
17. Hajjar, A. M., and M. L. Linial. 1995. Modification of retroviral RNA by double-stranded RNA adenosine deaminase. J. Virol. 69:5878-5882.
18. +-infected individuals discordant for clinical status. Mol. Ther., in press.
19. Jacque, J. M., K. Triques, and M. Stevenson. 2002. Modulation of HIV-1 replication by RNA interference. Nature 418:435-438.
20. Kim, J. H., R. J. McLinden, J. D. Mosca, M. T. Vahey, W. C. Greene, and R. R. Redfield. 1996. Inhibition of HIV replication by sense and antisense rev response elements in HIV-based retroviral vectors. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 12:343-351.
21. Kumar, M., and G. G. Carmichael. 1997. Nuclear antisense RNA induces extensive adenosine modifications and nuclear retention of target transcripts. Proc. Natl. Acad. Sci. USA 94:3542-3547.
22. Kusunoki, A., T. Saitou, N. Miyano-Kurosaki, and H. Takaku. 2001. Inhibition of the human chemokine receptor CXCR4 by antisense phosphorothioate oligodeoxyribonucleotides. FEBS Lett. 488:64-68.
23. Lee, N. S., T. Dohjima, G. Bauer, H. Li, M.-J. Li, A. Ehsani, P. Salvaterra, and J. Rossi. 2002. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol. 19:500-505.
24. Little, S. J., S. Holte, J.-P. Routy, E. S. Daar, M. Markowitz, A. C. Collier, R. A. Koup, J. W. Mellors, E. Connick, B. Conway, M. Kilby, L. Wang, J. M. Whitcomb, N. S. Hellmann, and D. D. Richman. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:385-394.
25. Lu, X., L. Humeau, V. Slepushkin, G. Binder, Q. Yu, T. Slepushkina, Z. Chen, R. Merling, B. Davis, Y.-N. Chang, and B. Dropulic. Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol. J. Gen. Med., in press.
26. Mautino, M. R., and R. A. Morgan. 2002. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense. Gene Ther. 9:421-431.
27. Morel, F., S. Salimi, J. Markovits, T. W. Austin, and I. Plavec. 1999. Hematologic recovery in mice transplanted with bone marrow stem cells expressing anti-human immunodeficiency virus genes. Hum. Gene Ther. 10:2779-2787.
28. Morgan, R. A., and R. Walker. 1996. Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins. Hum. Gene Ther. 7:1281-1306.
29. Nijuis, M., S. Deeks, and C. Boucher. 2001. Implications of antiretroviral resistance on viral fitness. Curr. Opin. Infect. Dis. 14:23-28.
30. Novina, C. D., M. F. Murray, D. M. Dykxhoorn, P. J. Beresford, J. Riess, S. K. Lee, R. G. Collamn, J. Lieberman, P. Shankar, and P. A. Sharp. 2002. siRNA-directed inhibition of HIV-1 infection. Nat. Med. 8:681-686.
31. O'Hara, P. J., S. T. Nichol, F. M. Horodyski, and J. J. Holland. 1984. Vesicular stomatitis virus defective interfering particles can contain extensive genomic sequence rearrangements and base substitutions. Cell 36:915-924.
32. Patterson, J. B., and C. E. Samuel. 1995. Expression and regulation by interferon of a double-stranded RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Mol. Cell. Biol. 15:5376-5388.
33. Patterson, J. B., D. C. Thomis, S. L. Hans, and C. E. Samuel. 1995. Mechanism of interferon action: double-stranded RNA-specific adenosine deaminase from human cells is inducible by alpha and gamma interferons. Virology 210:508-511.
34. Paul, C. P., P. D. Good, I. Winer, and D. R. Engelke. 2002. Effective expression of small interfering RNA in human cells. Nat. Biotechnol. 29:505-508.
35. Powderly, W. G. 2002. Long-term exposure to lifelong therapies. J. Acquir. Immune Defic. Syndr. 29:S28-S40.
36. Qin, X.-F., D. S. An, I. Chen, and D. Baltimore. 2003. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl. Acad. Sci. USA 100:183-188.
37. Rigden, J. E., J. A. Ely, J. L. Macpherson, W. L. Gerlach, L. Q. Sun, and G. P. Symonds. 2000. The use of ribozyme gene therapy for the inhibition of HIV replication and its pathogenic sequelae. Curr. Iss. Mol. Biol. 2:61-69.
38. Rouzine, I. M., and J. M. Coffin. 1999. Search for the mechanism of genetic variation in the pro gene of human immunodeficiency virus. J. Virol. 73:8167-8178.
39. Rueda, P., B. Garcia-Barreno, and J. A. Melero. 1994. Loss of conserved cysteine residues in the attachment (G) glycoprotein of two human respiratory syncytial virus escape mutants that contain multiple A-G substitutions (hypermutations). J. Virol. 198:653-662.
40. Sarver, N., E. M. Cantin, P. S. Chang, J. A. Zaia, P. A. Ladne, D. A. Stephens, and J. J. Rossi. 1990. Ribozymes as potential anti-HIV-1 therapeutic agents. Science 247:1222-1225.
41. Shahabuddin, M., and A. S. Khan. 2000. Inhibition of human immunodeficiency virus type 1 by packageable, multigenic antisense RNA. Antisense Nucleic Acid Drug Dev. 10:141-151.
42. + T cells. Nat. Med. 9:727-728.
43. Spencer, C. A., R. D. Gietz, and R. B. Hodgetts. 1986. Overlapping transcription units in the dopa decarboxylase region of Drosophila. Nature 322:279-281.
44. Tsichlis, P. N. 1987. Oncogenesis by Moloney murine leukemia virus. Anticancer Res. 7:171-180.
45. Tung, F. Y., and M. H. Tung. 1996. Characterization of antisense RNA-mediated inhibition of SIV replication. J. Med. Virol. 48:321-325.
46. Turner, B. J. 1993. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J. Infect. Dis. 185:S143-S151.
47. UNAIDS Joint United Nations Programme on HIV/AIDS. 2003. AIDS epidemic update: December 2003. UNAIDS and World Health Organization, Geneva, Switzerland.
48. Veres, G., U. Junker, J. Baker, C. Barske, C. Kalfoglou, H. Ilves, S. Escaich, H. Kaneshima, and E. Bohnlein. 1998. Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication. J. Virol. 72:1894-1901.
49. Vigouroux, C., S. Gharakhanian, Y. Salhi, T. H. Nguyen, N. Adda, W. Rozenbasum, and J. Capeau. 1999. Adverse metabolic disorders during highly active antiretroviral treatments. Diabetes Metab. 25:383-392.
50. Williams, T., and M. Fried. 1986. A mouse locus at which transcription from both DNA strands produces mRNAs complementary at their 3′ ends. Nature 322:275-279.